Header

Prostate Cancer Clinical Trials

Category:Adult
Status:Active

Displaying all 24 trials

Proton Therapy vs. IMRT for Low or Intermediate Risk Prostate Cancer

We are studying whether men being treated for prostate cancer have the same amount of side effects from either one of two different external radiation treatments: IMRT or PBT. With IMRT, a number o...

Diagnosis: Prostate Cancer

Phase: 3

Protocol Number: 11-497

Enzalutamide in Androgen Deprivation Therapy With Radiation Therapy for High Risk, Clinically Localised, Prostate Cancer

The purpose of this study is to determine the effectiveness of enzalutamide as part of adjuvant androgen deprivation therapy (ADT) with a luteinizing hormone releasing hormone analogue (LHRHA) in m...

Diagnosis: Prostate Cancer, Radiation Oncology

Phase: 3

Protocol Number: 15-038

A Biomarker Study of Standard-of-care Radium-223 Chloride for Metastatic Castration-resistant Prostate Cancer

The purpose of this study is to look for markers of how Ra-223 improves the lives of men with prostate cancer. This study makes use of Ra-223 in the standard FDA-approved way, but adds non-standard...

Diagnosis: Prostate Cancer

Phase: 2

Protocol Number: 14-375

A Selective Androgen Receptor Modulator for Symptom Management in Prostate Cancer

This research study is studying the use of a targeted therapy called LY SARM, which is an investigational drug from a new class of molecules called Selective Androgen Receptor Modulators (SARMs) as...

Diagnosis: Prostate Cancer

Phase: 2

Protocol Number: 15-120

A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer

The main purpose of this study is to evaluate the safety and effectiveness of the study drug known as LY3023414 in combination with enzalutamide in men with prostate cancer.

Diagnosis: Prostate Cancer

Phase: 2

Protocol Number: 15-453

Neoadjuvant And Adjuvant Abiraterone Acetate + Aptilutamide Prostate Cancer Undergoing Prostatectomy

This research study is studying a combination of drugs called abiraterone acetate and ARN-509 as a possible treatment for new diagnosed Prostate Cancer. The following interventions will be use in t...

Diagnosis: Prostate Cancer

Phase: 2

Protocol Number: 16-223

NBTXR3 Nanoparticles and EBRT or EBRT With Brachytherapy in the Treatment of Prostate Adenocarcinoma

This study is a Phase 1/2 open-label involving 2 groups of patients newly diagnosed with either unfavorable intermediate risk or high risk prostate adenocarcinoma. One group will receive only EBRT ...

Diagnosis: Radiation Oncology, Prostate Cancer

Phase: 1 / 2

Protocol Number: 16-445

Circulating Tumor Cell Analysis in Patients With Localized Prostate Cancer Undergoing Prostatectomy

This study will evaluate a method to detect tumor cells that are circulating in the blood without getting a biopsy. The investigators already know from other studies that cancer tumors shed a small...

Diagnosis: Prostate Cancer

Phase: N/A

Protocol Number: 08-207

Focal MR-Guided Focused Ultrasound Treatment of Localized Low and Intermediate Risk Prostate Cancer

The hypothesis of this feasibility study is that focal treatment with ExAblate MRgFUS has the potential to be an effective non-invasive treatment for low risk, organ-confined prostate cancer, with ...

Diagnosis: Prostate Cancer

Phase:

Protocol Number: 13-184

Study of 18F-DCFPyL PET/CT Imaging in Patients With Prostate Cancer (OSPREY)

This study evaluates the safety and diagnostic performance characteristics of 18F-DCFPyL Injection in patients with at least high risk prostate cancer who are planned for radical prostatectomy with...

Diagnosis: Prostate Cancer

Phase:

Protocol Number: 16-539

An Efficacy and Safety Study of Niraparib in Men With Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies

The purpose of this study is to assess the efficacy, safety, and pharmacokinetics of niraparib in men with metastatic castration resistant prostate cancer (mCRPC) and deoxyribonucleic acid (DNA) re...

Diagnosis: Prostate Cancer

Phase:

Protocol Number: 16-493

Exercise Intervention Among Men With Prostate Cancer Initiating Androgen Deprivation Therapy

This research study is evaluating the impact and feasibility of a 12-week brisk walking and moderate strength training exercise intervention including a virtual component in men who are initiating ...

Diagnosis: Prostate Cancer

Phase:

Protocol Number: 16-515

An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS

The purpose of this study is to determine if apalutamide plus gonadotropin releasing hormone (GnRH) agonist in participants with high-risk, localized or locally advanced prostate cancer receiving p...

Diagnosis: Prostate Cancer

Phase:

Protocol Number: 16-244

A Study of Docetaxel + ARN-509 in Castration-Resistant Prostate Cancer

This research study is studying a combination of drugs as a possible treatment for castration-resistant prostate cancer. The interventions involved in this study are: - Docetaxel (a type of chemoth...

Diagnosis: Prostate Cancer

Phase:

Protocol Number: 16-485

Olaparib With or Without Cediranib in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

This randomized phase II trial studies how well olaparib with or without cediranib works in treating patients with castration-resistant prostate cancer that has spread to other places in the body. ...

Diagnosis: Prostate Cancer

Phase:

Protocol Number: 17-710

Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer

The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of ipatasertib plus abiraterone and prednisone/prednisolone compared with placebo plus abiraterone and prednisone...

Diagnosis: Prostate Cancer

Phase:

Protocol Number: 17-303

Genetic Counseling Processes and Outcomes Among Males With Prostate Cancer (ProGen)

This randomized controlled trial aims to evaluate the impact of pre-test video education and post-test genetic counseling as compared to in-person pre-test genetic counseling in males with advanced...

Diagnosis: Prostate Cancer

Phase:

Protocol Number: 17-409

Dose Escalation and Dose Expansion Study of GSK525762 in Combination With Androgen Deprivation Therapy and Other Agents in Subjects With Castrate-resistant Prostate Cancer

The study aims to evaluate the combination of GSK525762 with other agents that have been shown to be effective in the treatment of CRPC or metastatic CRPC, including approved agents (e.g., abirater...

Diagnosis: Prostate Cancer

Phase:

Protocol Number: 17-369

A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer

This is a randomized, open-label, three-arm, phase 3 study in men with biochemically recurrent prostate cancer and PSA doubling time ≤ 9 months at the time of study entry.

Diagnosis: Prostate Cancer

Phase:

Protocol Number: 17-384

Randomized Phase II Study of Salvage XRT + ADT +/- Abiraterone and Apalutamide for Rising PSA After RP (FORMULA-509)

This research study is comparing two different combinations of androgen deprivation therapy (ADT) used together with radiation as a treatment for rising PSA after radical prostatectomy (prostate ca...

Diagnosis: Prostate Cancer, Radiation Oncology

Phase:

Protocol Number: 16-623

Phase IB Trial of Radium-223 and Niraparib in Patients With Castrate Resistant Prostate Cancer (NiraRad)

This phase Ib trial studies the side effects and best dose of niraparib when given together with radium Ra223 dichloride in treating patients with prostate cancer that keeps growing even when the a...

Diagnosis: Prostate Cancer

Phase:

Protocol Number: 17-698

Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors

Avelumab in combination with talazoparib will be investigated in patients with locally advanced (primary or recurrent) or metastatic solid tumors, including non-small cell lung cancer (NSCLC), trip...

Diagnosis: Breast: Early Stage Disease, GYN: Ovarian, Fallopian, Peritoneal Cancer, Lung Cancer, Solid Tumor/Phase I, Prostate Cancer

Phase:

Protocol Number: 17-687

ProSTAR: A Study Evaluating CPI-1205 in Patients With Metastatic Castration Resistant Prostate Cancer

This is a two-arm, open label phase 1b/2 with an oral administration of CPI-1205 in combination with either enzalutamide or abiraterone/prednisone in male patients with metastatic Castration This s...

Diagnosis: Prostate Cancer

Phase:

Protocol Number: 18-112

PCM-075 in Combination With Abiraterone and Prednisone in Adult Patients With Metastatic Castration-Resistant Prostate Cancer

The purpose of the phase 2 study is to determine whether PCM-075 given orally once daily for 5 consecutive days every 21 days is safe and tolerable in adult patients with Metastatic Castration-Resi...

Diagnosis: Prostate Cancer

Phase:

Protocol Number: 18-117

'